Today, we are experiencing a real cultural revolution in the therapeutic approach to cancer
of the colon - rectum, that by orphan disease, it is now becoming an important paradigm of scientific
innovations and concepts.
Survival of patients with metastatic colorectal cancer (m-CRC) has been significantly improved with
the introduction of the monoclonal antibodies that have as target the vascular endothelial growth factor
(VEGF) and the epidermal growth factor receptor (EGFR).
The PD-1/PD-L1 pathway in cancer is implicated in tumors escaping immune destruction. This pathway
is up -regulated in many tumours. Blockade of this pathway with anti-PD-1 and anti-PD-L1 agents
has led to remarkable clinical responses in patients affected by many different types of cancer.
The aim of this review is to evaluate the effects of addiction of biological agents to standard chemotherapy
in the treatment of m-CRC.
We can say that, among the various treatment options, the challenge of the future will be a better selection
of the population, to ensure the best possible benefit from treatment with anti-VEGF drugs or
anti-EGFR and a careful and customized planning of the therapeutic strategy for each patient.